

ICAGEN INC  
Form SC 13G  
February 14, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**  
Washington, D.C. 20549  
**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

**Icagen, Inc.**

(Name of Issuer)

**Common Stock, \$0.001 par value**

(Title of Class of Securities)

**45104P104**

(CUSIP Number)

**December 31, 2005**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ICAGEN INC - Form SC 13G

CUSIP No. 45104P104

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
Abbott Laboratories  
  
36-0698440
2. Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)  N/A  
(b)  N/A
3. SEC Use Only
4. Citizenship or Place of Organization  
Illinois
- |   |    |                                     |
|---|----|-------------------------------------|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 5. | Sole Voting Power<br>1,646,535      |
|   | 6. | Shared Voting Power<br>None         |
|   | 7. | Sole Dispositive Power<br>1,646,535 |
|   | 8. | Shared Dispositive Power<br>None    |
9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,646,535
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   
N/A
11. Percent of Class Represented by Amount in Row (9)  
7.5%
12. Type of Reporting Person (See Instructions)  
CO

Edgar Filing: ICAGEN INC - Form SC 13G

Item 1.

- (a) Name of Issuer  
Icagen, Inc.
- (b) Address of Issuer's Principal Executive Offices  
4222 Emperor Boulevard, Suite 350  
  
Durham, North Carolina 27703

Item 2.

- (a) Name of Person Filing  
Abbott Laboratories
- (b) Address of Principal Business Office or, if none, Residence  
100 Abbott Park Road  
  
Abbott Park, Illinois 60064-6400
- (c) Citizenship  
Illinois
- (d) Title of Class of Securities  
Common Stock, \$0.001 par value
- (e) CUSIP Number  
45104P104

Item 3.

- If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  - (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  - (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  - (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
  - (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  - (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  - (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  - (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  - (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  - (j)  Group, in accordance with §240.13d-1(b)(1)(ii)(J).
- Not Applicable

Edgar Filing: ICAGEN INC - Form SC 13G

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:
  - 1,646,535 shares
- (b) Percent of class:
  - 7.5%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote
  - (ii) 1,646,535 shares  
Shared power to vote or to direct the vote
  - (iii) None  
Sole power to dispose or to direct the disposition of
  - (iv) 1,646,535 shares  
Shared power to dispose or to direct the disposition of
  - None

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

N/A

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item 10. Certification

N/A

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2006

Abbott Laboratories

By: /s/ Thomas C. Freyman  
Name: Thomas C. Freyman  
Title: Executive Vice President, Finance and  
Chief Financial Officer